|
Price
$16.78
|
Market Cap
11.97B
|
Sector
Technology
|
Div. Growth
-29.50%
|
|
P/E
16.7
|
P/B
1.59
|
P/S
4.0
|
Dividend %
1.10%
|
|
P/CF
12.6
|
P/FCF
18.1
|
Op. Cash Flow
1360.0
|
FCF/Share
0.9
|
|
Op. Margin
33.00%
|
Net Margin
33.30%
|
ROE
13.70%
|
ROI
10.10%
|
|
ROA
11.20%
|
EPS Growth
27.40%
|
Curr. Ratio
2.4
|
Debt/Equity
-
|
| Company | Price | P/E | Div. Yield | Market Cap ($Mil) | Rating |
|---|---|---|---|---|---|
| American Bio Medica Corporatio (ABMC) | $0.10 | - | - | 2.3M | |
| Axcelis Technologies Inc (ACLS) | $2.24 | - | - | 243.3M | |
| Aehr Test Systems (AEHR) | $2.80 | - | - | 30.3M | |
| Affymetrix, Inc. (AFFX) | $8.23 | - | - | 610.6M | |
| Applied Materials, Inc. (AMAT) | $16.50 | - | 2.30% | 20.81B |
Technology stocks have performed well during the past five years, especially in fast-growing emerging markets, where consumers have been forming lines around the block to snatch up iPads, smartphones and a host of other tantalizing devices.
Read more »There are many people who continue to hold a jaundiced view of stocks because they were traumatized by the last two recessions.
Read more »You'll recall that during the dot-com bubble, Wall Street asked us to throw out "outdated" fundamental analysis metrics like earnings and sales growth and return-on-equity.
Read more »
Please note that all recommendations are based on our model's results and do not represent our personal opinion. The stock Rating process is purely mechanical.
All analysis relies on publicly available financial information. Learn More
